Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus
- Kim, Soo Kyoung; Jung, Jaehoon; Jung, Jung Hwa; Yoon, NalAe; Kang, Sang Soo; Roh, Gu Seob; Hahm, Jong Ryeal
- Issue Date
- CHURCHILL LIVINGSTONE
- Adjuvant therapy; Hypoglycemic agents; Momordica charantia; Type 2 diabetes mellitus
- COMPLEMENTARY THERAPIES IN MEDICINE, v.52
- Journal Title
- COMPLEMENTARY THERAPIES IN MEDICINE
- Introduction: Momordica charantia (bitter melon) is widely used for its glucose-lowering effects. This study was conducted to assess the efficacy and safety of M. charantia as an adjuvant treatment in patients with type 2 diabetes. Methods: We performed a randomized, placebo-controlled study. Blood glucose levels, lipid profile, and adverse events were investigated after 12 weeks of treatment. Ninety subjects were included in the final analysis for glucose lowering efficacy of bitter melon. Results: There were no differences in age, sex, or glycated hemoglobin (HbA1c) levels between the bitter melon extract and placebo groups. After treatment with bitter melon extract for 12 weeks, the HbA1c levels of the bitter melon and placebo groups remained unchanged; however, the average fasting glucose level of the bitter melon group decreased (p = 0.014). No serious adverse events were reported during the treatment period. Conclusions: Our data showed that bitter melon has effects of glucose lowering in patients with type 2 diabetes.
- Files in This Item
- There are no files associated with this item.
- Appears in
- College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.